With the pipeline of healthcare and life sciences transactions burdened with higher financing costs, valuation gaps between sellers and buyers, and the impact of geopolitical, economic, and regulatory uncertainty, the sector is turning to fresh value creation models and a deeper focus on thorough deal preparation and due diligence.